~~<i id='BAB3FCFE5D'><strike id='BAB3FCFE5D'><tt id='BAB3FCFE5D'><pre id='BAB3FCFE5D'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：leisure time 2025-09-28 12:52:45 Page View：132

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Elizabeth Holmes banned from government health programs
Next article： The cancer drug shortage isn’t new — and neither are the solutions

explore

Duchenne breakthrough therapy leaves behind pioneering families

DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

For BCIs, commercial hurdles may be bigger than scientific ones

AdevicecomponentfromParadromicsInc.,oneofthemainbrain-computerinterfaceplayersracingtogettomarket.Co

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

What Mike Pence has said that could be used in a Donald Trump trial

1:11RepublicanpresidentialcandidateandformerVicePresidentMikePencespeakswiththemediaduringastopatthe